 |
인쇄하기
취소
|
Daewoong and AstraZeneca Korea to co-market Symbicort in Korea
Daewoong Pharmaceutical and AstraZeneca Korea (AZK) Monday announced that the two companies have signed an agreement to co-market Symbicort (budesonide/formoterol) in Korea, in addition to Nexium.
Launched in 2001, Symbicort is a combination formulation used in the management of asthma and chronic obstructive pulmonary disease (COPD). The drug has shown some efficacy as a medicine not only u...
Launched in 2001, Symbicort is a combination formulation used in the management of asthma and chronic obstructive pulmonary disease (COPD). The drug has shown some efficacy as a medicine not only u...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.